Clinical trials
Relapsed clinical trials
Below are recruiting relapsed clinical trials, each written for real people, not researchers. We’re tracking 892 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05726110RecruitingPhase 3
Selinexor for relapsed or refractory AML in combination treatments
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
Taiyuan, ShanxiAges 18–60 - NCT05806580RecruitingPhase 4
Second relma-cel infusion for returning B-cell lymphoma
This trial looks at giving a second dose of relma-cel (a type of CAR-T therapy) for B-cell lymphoma that came back or did not fully respond after the first treatment. It may help shrink tumors again, but it requires that side effects from the first treatment and pre-chemo are mostly gone and that you meet infection and blood-test safety checks.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07681596RecruitingPhase 1/Phase 2
Study of a new drug for relapsed or refractory multiple myeloma
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Duarte, CaliforniaAges 18 years+ - NCT06681623Recruiting
Ublituximab in older adults with relapsing MS
This study is testing how safe and effective the medication ublituximab is for older adults (ages 55–80) with relapsing multiple sclerosis. It aims to see if this treatment works well for this age group.
Foxborough, MassachusettsAges 55–80 - NCT07623798RecruitingPhase 3
Testing IBI3003 for relapsed or refractory multiple myeloma
This study tests a new drug called IBI3003 in people whose multiple myeloma (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can shrink the cancer and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06612944RecruitingPhase 2
Preventing relapse after stem cell transplant for high-risk MDS
This trial tests whether giving medication after a donor stem cell transplant can prevent the return of very high-risk myelodysplastic syndrome (MDS). It is for people who have a suitable donor and are healthy enough for the procedure.
ShanghaiAges 18–70 - NCT07604909RecruitingPhase 2
Serplulimab plus chemotherapy for early-relapsed colorectal cancer
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
ShanghaiAges 18 years+ - NCT07579234RecruitingPhase 3
New drug F182112 for hard-to-treat multiple myeloma
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
TianjingAges 18 years+ - NCT06496048RecruitingPhase 3
Testing lurbinectedin for small cell lung cancer that has returned
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
Jilin CityAges 18 years+ - NCT06732232RecruitingEarly Phase 1
CAR-T therapy for multiple myeloma that returned or didn't respond
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
ShanghaiAges 18–75 - NCT05967416RecruitingPhase 1
Early-phase lymphoma trial testing a new targeted immune treatment
This Phase 1 study tests SIRPant-M, a new immune-based treatment, in adults with lymphoma that has come back or not responded to earlier care. It may help by shrinking lymphoma using either the drug alone or the drug plus a targeted radiation treatment for certain lymphoma types.
Duarte, CaliforniaAges 18 years+ - NCT07519187RecruitingEarly Phase 1
CAR-T Cell Therapy for Hard-to-Treat Blood Cancers
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack cancer cells in patients with multiple myeloma, plasmacytoma, plasma cell leukemia, or light chain amyloidosis that have not responded well to previous treatments. The goal is to see if this approach can help patients whose cancers have become resistant to standard medicines.
Chengdu, ChengduAges 18–75 - NCT07502287RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for children with neuroblastoma
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
Shenzhen, GuangdongAges 1–21 - NCT07502768RecruitingPhase 1/Phase 2
Tislelizumab and Zeprumetostat for Lymphoma
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07481669RecruitingPhase 2
Stem cell transplant for lymphoma at high risk of brain relapse
This trial tests a stem cell transplant with a special chemo combination (TEAM) to see if it can prevent lymphoma from coming back in the brain or spinal cord for people with high-risk non-Hodgkin lymphoma.
Hangzhou, ZhejiangAges 18–70 - NCT07479797RecruitingPhase 3
Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
Goodyear, ArizonaAges 18 years+ - NCT07479979RecruitingPhase 1/Phase 2
Study of selinexor with carfilzomib, isatuximab and dexamethasone for relapsed/refractory multiple myeloma
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
Madison, WisconsinAges 18 years+ - NCT07471841RecruitingPhase 2
Olutasidenib for IDH1-mutated AML after venetoclax
This trial tests the drug olutasidenib for people with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. It is for patients who have already received the drug venetoclax and have an IDH1 mutation in their leukemia cells.
Winston-Salem, North CarolinaAges 18 years+ - NCT07460362RecruitingPhase 2
Glofitamab and lenalidomide for high-risk mantle cell lymphoma
This trial tests a combination of two drugs, glofitamab and lenalidomide, for people with mantle cell lymphoma that has come back or not responded to treatment. It's for those with high-risk features, like a fast-growing lymphoma or resistance to previous therapies.
Beijing, Beijing MunicipalityAges 18–80 - NCT06791681RecruitingEarly Phase 1
ESO-T01 for returning or hard-to-treat multiple myeloma
This trial tests a new treatment called ESO-T01 for people with multiple myeloma that has come back or is not responding to at least two prior therapies. It aims to see if this therapy is safe and can help control the disease.
Wuhan, HubeiAges 18 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Gilbert, ArizonaAges 18 years+ - NCT07397975Recruiting
Using speech to predict relapse in psychosis
This study uses speech recordings from a smartphone app to see if changes in the way you talk can predict when someone might have a relapse of psychosis. It is for people who are currently stable or for healthy volunteers to compare.
KlecanyAges 18–65 - NCT07382739RecruitingPhase 2
Radiation and immunotherapy for advanced multiple myeloma
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
Houston, TexasAges Any age - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25
Hear when a new Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed?
- Yes. Clin2 currently lists 892 recruiting relapsed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.